Kevzara (sarilumab) is an injectable medication FDA-approved to treat three inflammatory conditions: rheumatoid arthritis in adults, polymyalgia rheumatica in adults, and polyarticular juvenile idiopathic arthritis in younger patients. It was first approved in 2017 for rheumatoid arthritis and has since gained additional approvals. All three conditions involve the immune system attacking the body’s own tissues, and Kevzara works by blocking a specific inflammatory signal that drives that process.
Conditions Kevzara Treats
Kevzara is not a first-line treatment for any of its approved uses. It’s reserved for people who haven’t improved enough on other therapies or who can’t tolerate them.
For rheumatoid arthritis (RA), Kevzara is approved for adults with moderately to severely active disease who have already tried one or more disease-modifying antirheumatic drugs (DMARDs) like methotrexate without adequate relief. RA causes chronic joint pain, swelling, and stiffness, and without effective treatment it progressively damages the joints.
For polymyalgia rheumatica (PMR), it’s approved for adults who haven’t responded well to corticosteroids or who can’t successfully taper off them. PMR causes widespread aching and stiffness in the shoulders, neck, and hips, and many patients end up stuck on steroids for months or years because flares return whenever the dose drops. Kevzara offers a way to get off steroids while keeping symptoms controlled.
For polyarticular juvenile idiopathic arthritis (pJIA), it’s approved for patients weighing 63 kg (about 139 pounds) or more. This form of childhood arthritis affects five or more joints and can interfere with normal growth and activity.
How Kevzara Works
Kevzara belongs to a class of drugs called IL-6 receptor antagonists. IL-6 is a signaling molecule your immune system produces during inflammation. In autoimmune conditions like RA and PMR, the body overproduces IL-6, which ramps up inflammation in the joints and surrounding tissues. Kevzara binds to IL-6 receptors on the surface of cells and in the bloodstream, blocking that signal from getting through. With the inflammatory cascade dialed down, joint swelling, pain, and tissue damage slow considerably.
How Well It Works for Rheumatoid Arthritis
Two large phase 3 trials tested Kevzara against placebo in adults with RA who weren’t getting enough relief from other medications. By 24 weeks, 58% to 66% of patients on Kevzara achieved at least a 20% improvement in symptoms (the standard benchmark known as ACR20), compared to 33% to 34% on placebo. Roughly 37% to 47% hit the higher bar of 50% improvement, versus 17% to 18% on placebo.
The most meaningful results were at the highest threshold: 16% to 25% of Kevzara patients achieved 70% improvement in their symptoms, compared to just 7% on placebo. These numbers reflect real, measurable changes in tender and swollen joint counts, pain levels, and physical function.
How Well It Works for Polymyalgia Rheumatica
The SAPHYR trial compared Kevzara plus a rapid 14-week steroid taper against placebo plus a longer 52-week steroid taper. Among patients on Kevzara, 31.7% achieved sustained remission from week 24 through week 52, compared to 10.3% in the comparator group. Sustained remission meant no PMR symptoms, normalized inflammation markers, no disease flares, and successful completion of the steroid taper. For people who have been unable to get off corticosteroids, that three-to-one advantage is significant, since long-term steroid use carries its own serious risks including bone loss, weight gain, and elevated blood sugar.
How Kevzara Compares to Actemra
Actemra (tocilizumab) is the other major IL-6 receptor blocker used for RA, so patients often wonder how the two stack up. A large retrospective study using real-world data from nearly 2,000 matched patients in each group found similar cardiovascular outcomes between the two drugs. One notable difference: Actemra was associated with higher all-cause mortality compared to Kevzara (5.6% vs. 3.7%). That difference was driven largely by male patients, where the gap was statistically significant. In women, the mortality difference was not significant. These are observational findings rather than results from a head-to-head randomized trial, so they should be interpreted with some caution, but they suggest the two drugs are not interchangeable in every respect.
How You Take It
Kevzara is a subcutaneous injection, meaning it goes just under the skin rather than into a vein. The standard dose is 200 mg every two weeks. After initial training from a healthcare professional, most patients give themselves the injection at home using a prefilled syringe or pen. You can inject into your thigh or abdomen (avoiding the two-inch area around your belly button). If someone else is giving you the injection, the outer upper arm is also an option. The every-two-week schedule is the same for RA and PMR.
For PMR specifically, Kevzara is started alongside a tapering course of corticosteroids. The goal is to use Kevzara to control the disease while gradually reducing and eventually stopping steroids, then continuing Kevzara alone.
Side Effects and Monitoring
Because Kevzara suppresses part of the immune system, the most important risk is serious infections. The drug carries a boxed warning about this. Infections that would normally be minor can become severe in people taking Kevzara, and latent infections like tuberculosis can reactivate. Your doctor will test for tuberculosis before starting treatment.
Some patients experience injection site reactions like redness or itching, which are typically mild. Kevzara can also lower your white blood cell counts, particularly a type called neutrophils that help fight bacterial infections. It may raise liver enzyme levels and increase cholesterol. Because of these effects, you’ll need regular blood tests, especially in the first few months. Your dose may be reduced from 200 mg to 150 mg if your lab values shift beyond certain thresholds, and treatment may be paused temporarily if counts drop too low.
Live vaccines should not be given while you’re on Kevzara, since the suppressed immune response could allow a live vaccine virus to cause illness rather than just immunity. Make sure any needed vaccinations are up to date before starting treatment.